Filing summary
Entity mismatch: The supplied filing is Helix Acquisition Corp.’s Form 10-Q, not a filing by MoonLake Immunotherapeutics. It reports for the quarter and six months ended June 30, 2021; the filing identifies Helix as a Cayman Islands blank-check company (ticker HLXA), formed to pursue a business combination. It had not commenced operating business activities and reported no operating revenue.
Financial performance and position
| Metric | Three months ended June 30, 2021 | Six months ended June 30, 2021 |
|---|---|---|
| General and administrative expenses | $158,473 | $252,579 |
| Interest income from trust investments | $6,140 | $23,955 |
| Net loss | $152,333 | $228,624 |
| Operating cash used | Not presented for quarter | $180,165 |
- At June 30, cash outside the trust was $1.10 million; trust investments were $115.04 million; total assets were $116.37 million.
- Current liabilities were $90,000, total liabilities $4.12 million, and shareholders’ equity $5.00 million. The $4.03 million deferred underwriting fee is payable only if a business combination is completed. No working-capital loan was outstanding; the filing reports no long-term debt.
- Working capital was approximately $1.2 million. The company reported no off-balance-sheet financing arrangements. Revenue and operating margins are not applicable because the company had no operations or operating revenue.
Changes and outlook
- Compared with December 31, 2020, cash declined by about $238,000, current liabilities fell from $125,183 to $90,000, and trust assets increased from $115.01 million to $115.04 million. The filing does not provide comparable 2020 quarterly operating results.
- Management believed available working capital and borrowing capacity would fund needs through the earlier of a business combination or one year from the filing. It expected spending on target search, due diligence, and transaction costs; additional financing might be needed if costs exceeded estimates or redemptions were substantial.
- The company had until October 22, 2022—24 months after its IPO—to complete a business combination. Otherwise, it must stop operations, redeem public shares from the trust (subject to stated terms), and wind up.
- COVID-19 could adversely affect the company or its target search, but the filing said the specific impact was not determinable. Trust investments could also earn negative interest, potentially reducing redemption proceeds below $10 per public share.
- Management said disclosure controls were effective, but a previously identified material weakness in internal control over financial reporting had not been fully remediated as of June 30, 2021. No material changes to the prospectus risk factors were reported.
Key investor verification points
- Confirm the filing belongs to Helix Acquisition Corp., not MoonLake Immunotherapeutics, before relying on it for MoonLake analysis.
- Verify business-combination status, the October 22, 2022 deadline, and any subsequent amendments or transaction announcements.
- Review the number and terms of redeemable public shares, trust assets, and the deferred underwriting fee when assessing cash available at a transaction.
- Review remediation of the disclosed material weakness and the filing’s per-share loss presentation; the extracted statements appear inconsistent on the three-month non-redeemable per-share amount.